These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24699471)

  • 61. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
    Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
    Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017.
    Li Z; Xu J; Tan H; Zhang C; Chen J; Ni L; Yun X; Huang Y; Wang W
    Int J Infect Dis; 2020 Oct; 99():149-155. PubMed ID: 32795602
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
    Happe LE; Lunacsek OE; Kruzikas DT; Marshall GS
    Pediatr Infect Dis J; 2009 Feb; 28(2):98-101. PubMed ID: 19148039
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recommended childhood immunization schedule--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(2):35-40. PubMed ID: 9011782
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
    Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
    Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
    Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study.
    Zhu Y; Sun L; Wang Y; Wang J; Wang Y; Li J; Wang L; Guo Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2372884. PubMed ID: 38957938
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine.
    Gyhrs A; Lyngholm E; Larsen SO; Aggerbeck H; Heron I
    Scand J Infect Dis; 1999; 31(6):579-85. PubMed ID: 10680989
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
    Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
    Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.
    Berner R; Boisnard F; Thomas S; Mwawasi G; Reynolds D
    Vaccine; 2012 Jul; 30(35):5270-7. PubMed ID: 22691430
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids.
    Nakayama T; Aizawa C; Kuno-Sakai H
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):321-5. PubMed ID: 9949325
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants.
    Faldella G; Galletti S; Corvaglia L; Ancora G; Alessandroni R
    Vaccine; 2007 Jan; 25(6):1036-42. PubMed ID: 17088013
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
    Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E
    Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
    Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
    Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.